The FDA just approved a new drug to treat eczema that costs $37,000 a year
The FDA on Tuesday approved Regeneron Pharmaceuticals and Sanofi's Dupixent for treatment of moderate to severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies. Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes intense constant itching.
from Biotech News
0 Comments